BibTex format
@article{Berardi:2019:10.21037/atm.2019.09.18,
author = {Berardi, R and Santoni, M and Rinaldi, S and Bower, M and Tiberi, M and Morgese, F and Caramanti, M and Savini, A and Ferrini, C and Torniai, M and Fiordoliva, I and Newsom-Davis, T},
doi = {10.21037/atm.2019.09.18},
journal = {Ann Transl Med},
title = {Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer.},
url = {http://dx.doi.org/10.21037/atm.2019.09.18},
volume = {7},
year = {2019}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: Inflammation plays an important role in pathogenesis, development and progression of lung cancer. The aim of the study is to assess the prognostic role of Systemic Immune-Inflammation Index (SII), obtained by analyzing the neutrophil, lymphocyte and platelet counts, and to design prognostic models for patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC). METHODS: We conducted an analysis on 311 patients with advanced NSCLC, treated with first line chemo- or targeted therapy till June 2015 at our Institution. Patients were stratified in two groups with SII ≥1,270 (Group A) vs. SII <1,270 (Group B). Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. The best SII cutoff was identified by X-tiles program. A Cox regression model was carried out for univariate and multivariate analyses. RESULTS: At baseline, 179 patients had SII ≥1,270 (Group A), whilst 132 had lower SII (Group B). The median OS was 12.4 months in Group A and 21.7 months in Group B (P<0.001), whilst the median PFS was 3.3 and 5.2 months, respectively (P=0.029). At multivariate analysis, male gender, ECOG-PS ≥2 and SII >1,270 were predictors of worst OS, whilst IV tumor stage was only slightly significant (P=0.08). Otherwise, only wild-type EGFR status and SII ≥1,270 were independent prognostic factors for worst PFS. CONCLUSIONS: Pre-treatment SII is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.
AU - Berardi,R
AU - Santoni,M
AU - Rinaldi,S
AU - Bower,M
AU - Tiberi,M
AU - Morgese,F
AU - Caramanti,M
AU - Savini,A
AU - Ferrini,C
AU - Torniai,M
AU - Fiordoliva,I
AU - Newsom-Davis,T
DO - 10.21037/atm.2019.09.18
PY - 2019///
SN - 2305-5839
TI - Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer.
T2 - Ann Transl Med
UR - http://dx.doi.org/10.21037/atm.2019.09.18
UR - https://www.ncbi.nlm.nih.gov/pubmed/31807553
VL - 7
ER -